Blood Loss, Surgical

5
Pipeline Programs
3
Companies
7
Clinical Trials
1
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
3
1
Early DiscoveryClinical DevelopmentMarket

On Market (1)

Approved therapies currently available

Bayer
TRASYLOLApproved
aprotinin
Bayer
injection1993

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Bayer
BayerLEVERKUSEN, Germany
3 programs
3
1
TRASYLOL(Trasylol)Phase 33 trials
TrasylolPhase 31 trial
TrasylolPhase 31 trial
Active Trials
NCT00611845No Longer Available
NCT00327379Terminated54Est. Mar 2007
NCT00668031Completed359Est. Jan 2006
+2 more trials
CSL Behring
CSL BehringIL - Bradley
1 program
1
Haemate HSPhase 21 trial
Active Trials
NCT00618293Withdrawn0Est. Jul 2011
Artivion
ArtivionKENNESAW, GA
1 program
PerClot Polysaccharide Hemostatic SystemN/A1 trial
Active Trials
NCT02359994CompletedEst. Feb 2019

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
BayerTrasylol
BayerTrasylol
BayerTrasylol
BayerTrasylol
CSL BehringHaemate HS
ArtivionPerClot Polysaccharide Hemostatic System

Clinical Trials (7)

Total enrollment: 574 patients across 7 trials

Effect of Aprotinin on Transfusion Requirements in Patients Undergoing Elective Spinal Fusion Surgery

Start: Feb 2006Est. completion: Mar 200754 patients
Phase 3Terminated

Study to Investigate the Effect of Aprotinin of Transfusion Requirements in Patients Undergoing Surgical Procedures for Lung or Esophageal Cancer

Start: Dec 2005Est. completion: Mar 2007104 patients
Phase 3Terminated

Efficacy and Safety of Aprotinin on Transfusion Requirements in Patients Undergoing Radical or Total Cystectomy

Start: Dec 2005Est. completion: Mar 200757 patients
Phase 3Terminated

Effect of Aprotinin on Transfusion Requirements and Blood Loss in Patients Undergoing Elective Primary Total Hip Replacement

Start: Feb 2005Est. completion: Jan 2006359 patients
Phase 3Completed

Haemate HS in Patients With Severe Bleeding Undergoing Valve Replacement Due to Aortic Stenosis

Start: Jan 2008Est. completion: Jul 20110
Phase 2Withdrawn

Aprotinin US Special Access Protocol

N/ANo Longer Available
NCT02359994ArtivionPerClot Polysaccharide Hemostatic System

Prospective, Multicenter, Multidisciplinary, Controlled Clinical Investigation Evaluating the Safety and Efficacy of PerClot® Polysaccharide Hemostatic System

Start: Apr 2015Est. completion: Feb 2019
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

3 late-stage (Phase 3) programs — potential near-term approvals
3 companies competing in this space